falsefalse

Evolving Treatment Landscape in Myelodysplastic Syndromes - Episode 8

ESA Treatment Selection in MDS

, , ,

Clinical insights on selecting appropriate erythropoiesis-stimulating agents in patients with myelodysplastic syndromes.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Diagnosis of Myelodysplastic Syndromes (MDS)
    EP. 2: Risk Stratification of Myelodysplastic Syndromes
    EP. 3: First-Line Treatment of Lower-Risk MDS with Symptomatic Anemia
    EP. 4: Patient Profile 1: A 72-Year-Old Man With MDS
    EP. 5: Second-Line Treatment of Lower-Risk MDS With Symptomatic Anemia
    EP. 6: Patient Profile 2: A 77-Year-Old Man With MDS
    EP. 7: Unmet Needs and Adverse Event Management for Patients With Lower-Risk MDS and Symptomatic Anemia
    Now Viewing
    EP. 8: ESA Treatment Selection in MDS
    EP. 9: Updates from COMMANDS Trial: Luspatercept in Lower-Risk MDS
    EP. 10: Retrospective Claims Data and Patient Reported-Outcomes from COMMANDS Trial in Lower-Risk MDS
    EP. 11: IMerge: Imetelstat in Patients With Lower-Risk MDS
    EP. 12: Cytopenias Following Imetelstat Treatment in Lower-Risk MDS
    EP. 13: Emerging Clinical Trials in MDS and Key Takeaways from ASH 2023
    EP. 14: Treatment Options and Unmet Needs in Higher-Risk MDS
    EP. 15: Updates from ASH 2023 in Higher-Risk MDS
    EP. 16: Takeaways from ASH 2023 in Higher-Risk MDS
    EP. 17: Closing Thoughts on the MDS Treatment Landscape

    Related Content:

    Evolving Treatment Landscape in Myelodysplastic SyndromesSidney Kimmel Comprehensive Cancer Center at Johns HopkinsRobert H. Lurie Comprehensive Cancer Center of Northwestern University Northwestern MedicineHematologic OncologyOncLive Peer Exchange®
    Insights From Liso-cel Combined With Ibr for R/RCLL/SLL: Primary Results From the Open-Label, Phase 1/2 Transcend CLL 004 Study
    Overview of the Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients With Previously Untreated DLBCL Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial
    FDA Lifts Clinical Hold on Tabelecleucel Trial for EBV+ Post-Transplant Lymphoproliferative Disease
    x